Safralis saffron

The question

Does eight weeks of consistent Safralis use improve my overall mood enough to matter in daily life? Enjoyment, stress reactivity and daytime alertness will show what that change feels like. Sleep is a secondary observation.

Product and selected amount

I have Nootropics Depot Safralis in 15 mg capsules. My selected plan is one capsule twice daily, for a total of 30 mg/day, throughout the 56-day intervention. That requires 112 capsules. The amount stays fixed during the main experiment; any later amount comparison would be a separate phase.

The manufacturer describes Safralis as cold-milled whole Kashmir saffron stigma, standardized to 8% crocins and 3% safranals. Safranals is a group including safranal and its precursors, picrocrocin and HTCC. It does not mean 3% pure safranal.

Daily timing

The planned first capsule is after my usual wake-up, and the second is about six to eight hours later. I will choose consistent time windows and keep the relationship to food the same each day. The spacing is for a repeatable routine, rather than a measured Safralis effect duration. Both administrations are logged separately. A missed capsule is recorded as missed, without an extra catch-up capsule.

Full sequence

The intervention and follow-up cover 70 days, or 10 weeks, after a single pre-start reference entry. The two weeks after stopping are an observation period, not an established pharmacological washout. This first run is an open-label intervention and follow-up comparison.

Starting point and surrounding routine

I have chosen to start on October 21, without waiting for the October 29 checkpoint or adding a two-week baseline. Before starting, I will record my current mood, enjoyment, stress reactivity and sleepiness, and complete WHO-5. The reference entry is planned for the evening of October 20. Its actual time will be recorded; a missed entry stays missing rather than being reconstructed. The scheduled start is not confirmation that the first capsule has been taken.

I will keep caffeine, established mood-related supplements, sleep schedule, training rotation and calorie intake as consistent as practical. I will run new cognitive or sleep experiments separately. Changes that do occur stay in the log, with their dates, rather than disappearing from the final interpretation.

Four evening ratings

About one hour before my intended bedtime, I will score the day using the same anchors, before reviewing previous scores. The same routine applies to the pre-start entry, intervention and follow-up.

I will also mark workload as low, usual or high, and add one short note about an unusual stressor, illness, travel, or a noticeable real-life change. A calm day with no stressor stays distinct from handling a difficult day well. Missed ratings remain missing; they are not reconstructed later or entered as zero.

WHO-5 every two weeks

I will complete the same WHO-5 well-being questionnaire before the first dose, on intervention days 14, 28, 42 and 56, and on follow-up day 70. The scheduled follow-up questionnaires fall on November 3, November 17, December 1, December 15 and December 29. The pre-start questionnaire covers the preceding two weeks, and later questionnaires retain the same two-week recall. This supports the daily mood record with a consistent broader view of well-being.

Sleep, alertness and adherence

Existing WHOOP sleep duration, resting heart rate and HRV provide supporting context. I will note perceived sleep quality and any unusual waking or next-day grogginess. Dose time, missed capsules and changes in other supplements or medicines belong beside these observations. No new bloodwork is planned solely for this mood question.

Review points

Days 14 and 28 are checks on adherence, observations and how the routine feels, without automatic escalation. Day 56 is the main assessment; day 70 closes the follow-up. I will retain early impressions, but judge sustained benefit using the final four intervention weeks.

Primary comparison

I will compare mean overall mood during intervention days 29 to 56, November 18 to December 15, with the single pre-start rating, alongside the change in WHO-5 from its pre-start score. The reference is one observation, not a two-week mood average. I will also show weekly averages and the daily record. The first week is already on Safralis and will not be relabeled as an untreated baseline. Enjoyment, stress reactivity, sleepiness and WHO-5 remain separate outcomes.

What would count as helpful

• Mean mood is at least one point higher on the 0-to-10 scale in the final four intervention weeks than the pre-start rating.
• At least three of those four weekly means are at least one point above the pre-start rating.
• The change comes with a worthwhile everyday difference, such as enjoying activities more or recovering from frustration faster.
• Daytime alertness remains acceptable to me, and any sleep or other tradeoff is recorded alongside the benefit.

One point is my predefined personal usefulness threshold, not a validated clinical minimum. If mood is already near the top of the scale in the pre-start entry, I will document any change to the primary question before the first capsule, rather than choose a more favorable outcome after seeing results.

Measurement coverage and interruptions

I want the pre-start rating and WHO-5, plus at least six daily ratings in each seven-day intervention week used in the main assessment. Sparse weeks are marked incomplete. If the pre-start entry is missing, I will describe the on-treatment trend and real-life observations without inventing a before-and-after numerical comparison. Missing intervention data may leave the primary result inconclusive.

If illness, travel or a substantial routine change interrupts the run, I will show those days and summarize them separately. A major change may require a new comparison segment. I will not quietly remove difficult days or extend the run until the result becomes positive.

Stopping and follow-up

Persistent worsening of mood, agitation, sleep disruption or daytime grogginess that matters to me ends the active phase for reassessment. Any early stop and its reason will be documented. Otherwise, I stop after day 56 and keep the same observations for another 14 days.

Benefit that continues after stopping still counts as an observed benefit. I do not require deterioration during follow-up to call the run helpful. A clear result could justify a later blinded repeat; continued use is a separate decision.

Result labels

Helpful means the primary goal improved enough to keep or revisit. Mixed means benefits and tradeoffs coexist, or only secondary outcomes improve. No signal means an adequately observed run produces no worthwhile change. Inconclusive means interruptions or missing observations prevent a useful assessment. No result has been assigned yet.

Why mood and stress

A four-week randomized trial of affron in adults reporting low mood found improvements in mood-related outcomes at 28 mg/day. An eight-week trial of Safr'Inside in healthy adults reporting low mood found changes in selected mood and stress-response measures. These studies make the everyday mood question worth asking and support observing changes over weeks.

Why sleep stays secondary

A separate 28-day affron trial in adults with unsatisfactory sleep reported improved subjective sleep quality. My main question here is mood, with sleep and morning alertness tracked as related outcomes rather than used to redefine the experiment afterward.

The product distinction

Those trials used specific saffron extracts. Safralis uses whole saffron with its own standardization. My 30 mg daily total is a selected personal exposure to this product, not a claim of equivalent active exposure to 28 or 30 mg of another preparation.

• Nootropics Depot: Safralis: manufacturer description of the whole-saffron formulation, capsule sizes and standardization.
• Kell et al., 2017: four-week randomized trial of affron and mood in healthy adults reporting low mood.
• Jackson et al., 2021: eight-week saffron-extract study of mood, well-being and stress response.
• Lopresti et al., 2021: 28-day affron study in adults with unsatisfactory sleep.
• World Health Organization: WHO-5: the five-item well-being questionnaire with a two-week recall period.